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Background: Plumbagin is the major active constituent in several plants including Plumbago indica Linn. (root).
This compound has been shown to exhibit a wide spectrum of biological and pharmacological activities. The
present study aimed to evaluate the in vitro and in vivo antimalarial activity of plumbagin including its acute
and subacute toxicity in mice.
Methods: In vitro antimalarial activity of plumbagin against K1 and 3D7 Plasmodium falciparum clones were
assessed using SYBR Green I based assay. In vivo antimalarial activity was investigated in Plasmodium berghei-
infected mouse model (a 4-day suppressive test).
Results: Plumbagin exhibited promising antimalarial activity with in vitro IC50 (concentration that inhibits parasite
growth to 50%) against 3D7 chloroquine-sensitive P. falciparum and K1 chloroquine-resistant P. falciparum clones
of 580 (270–640) and 370 (270–490) nM, respectively. Toxicity testing indicated relatively low toxicity at the dose
levels up to 100 (single oral dose) and 25 (daily doses for 14 days) mg/kg body weight for acute and subacute
toxicity, respectively. Chloroquine exhibited the most potent antimalarial activity in mice infected with P. berghei
ANKA strain with respect to its activity on the reduction of parasitaemia on day 4 and the prolongation of
survival time.
Conclusions: Plumbagin at the dose of 25 mg/kg body weight given for 4 days was safe and produced weak
antimalarial activity. Chemical derivatization of the parent compound or preparation of modified formulation is
required to improve its systemic bioavailability.
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Malaria is widespread in tropical and subtropical regions.
Throughout the history of mankind, this highly infectious
disease has been one of the major causes of human illness
and death. Chemotherapy with effective antimalarial drugs
remains the mainstay for malaria control in the absence of
a suitable vaccine treatment. Plasmodium falciparum is
the most virulent and widespread infectious malarial spe-
cies in tropical and subtropical countries due to the resist-
ance of the parasite to most of the available antimalarial
drugs [1]. In a race to combat the increasing multidrug
resistance P. falciparum, artemisinin-based combination* Correspondence: kesaratmu@yahoo.com
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reproduction in any medium, provided the ortherapy (ACT) has been recommended by the World
Health Organization (WHO) as the first-line treatment for
acute uncomplicated multidrug resistance P. falciparum
malaria in all the malaria endemic areas of the world. As
antimalarial drug resistance compromises the effective
treatment of the disease, there is a pressing need for
ongoing drug discovery research that will provide effect-
ive, safe, and affordable antimalarial agents. Natural prod-
ucts including medicinal plants may offer relatively cheap
alternative treatment opportunities for malaria patients
[2,3]. Two antimalarial drugs currently widely used for
malaria control originally came from indigenous medicinal
plants; quinine is isolated from the Peruvian Cinchona's
bark and artemisinins are obtained from the Chinese plant
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is a natural product isolated from several plants in the
families of Plumbaginaceae, Droseraceae, Ancestroclada-
ceae, and Dioncophyllaceae. It is a naphthoquinone that
occurs in plant roots as a colorless combined form that
can be processed to plumbagin by acid treatment [4].
This compound has been shown to display a wide
spectrum of biological and pharmacological activities
such as activities against malaria, leishmania and tryp-
anosome parasites, as well as against virus, cancers, and
insects [5]. The ethanolic extract of Plumbago zeylanica
has been reported to exhibit in vitro antimalarial activity
against chloroquine-sensitive clone of P. falciparum
(3D7) with an IC50 (concentration that inhibits parasite
growth by 50%) of 17 μg/ml [6]. The activity against
P. falciparum enzyme succinate dehydrogenanse (SDH)
including parasite growth has been shown to be inhibited
to 50% by plumbagin at inhibitory concentrations of 5 and
0.27 mM, respectively [7]. Recently, our group has dem-
onstrated promising antimalarial activity of the ethanolic
extract of Plumbago indica Linn. [8]. The aim of the
present study was to further evaluate the in vitro and
in vivo antimalarial activity of its active constituent
plumbagin. In addition, acute and subacute toxicity tests
were performed to confirm its safety and tolerability, and




Plumbagin (purity 98.2%) was obtained from Apin
chemicals Co. Ltd. (Oxford, UK). Tween-80, and chloro-
quine diphosphate were obtained from Sigma-Aldrich
(St. Louis, MO, USA). RPMI 1640 powder containing
L-glutamine, streptomycin/penicillin, and HEPES were
obtained from Gibco BRL Life Technologies (Grand Island,
NY, USA). Gentamicin was obtained from Invitrogen Life
Technologies Inc. (Carlsbad, CA, USA).
In vitro experiment
In vitro cultivation of malaria parasite
Blood stages of the laboratory clones chloroquine-
resistant (K1) and chloroquine-sensitive (3D7) P. falcip-
arum were cultured in vitro according to the method of
Trager and Jensens [9]. All culture steps were performed
using aseptic technique in the NuAire laminar flow class
II safety cabinet. All glassware was autoclaved at 121°C
(15 atmosphere) for at least 15 min. Malaria parasite
was maintained in continuous culture with human
packed red blood cells (blood group O+) in RPMI 1640
medium supplemented with 10% human AB+ serum,
25 mM N-2-hydroxyethylpiperazine-N-2-ethanesulfonic
acid (HEPES), 25 mM sodium bicarbonate, and gentamy-
cin sulfate (60 μg/ml, pH 7.2). The culture was incubatedat 37°C in an atmosphere consisting of 90% N2, 5% O2,
and 5%. Parasite culture was synchronized to the ring
stage by treatment with 5% (w/v) D-sorbitol [10].
Assessment of in vitro antimalarial activity of Plumbagin
Antimalarial activity of plumbagin was investigated using
SYBR Green I assay [10,11]. Highly synchronous ring
stage parasite was used in each assay. An aliquot of
parasite inoculum (50 μl) with 2% parasitaemia and 1%
haematocrit was added into each well of microtiter plate.
Plumbagin (dissolved in DMSO and diluted with RPMI
1640 to final concentration of 1%) was added to the mal-
aria culture at eight final concentrations of 210, 420, 840,
1680, 3360, 6720, 13440, and 26880 nM. Chloroquine
(3.89-498.15 nM) and artesunate (0.39-50.0 nM) were
used as standard antimalarial drugs.
The experiment was repeated three times (triplicate
each). IC50 value (drug concentration that inhibits the
parasite growth by 50%) was used as an indicator of
antimalarial activity and was determined from a log-
dose–response curve plotted using the Calcusyn™ version
1.1 (BioSoft, Cambridge, UK).
In vivo experiments
Animals
ICR (Imprinting Control Region) mice (5–7 weeks of age,
weighting 20–40 g) of both sexes were used in the study.
All were obtained from the National Laboratory Animal
Centre, Thailand. Animal experiments were carried out in
accordance with the OECD Guideline for Chemicals [12].
The animals were housed under standard conditions
and fed with a stock diet and water ad labitum. Ap-
proval of the study protocol was obtained from the
Ethics Committee for Animal Research, Thammasat
University, Thailand.
Toxicity tests
Plumbagin was weighted and resuspended with 20%
Tween-80 to obtain the desired concentrations. ICR
mice were fasting 2 h before feeding with a single oral
dose of plumbagin. Animals were divided into eight
groups of six (3 males and 3 females for each group).
For the acute toxicity test, mice in each group were fed
with plumbagin at a single oral dose of 500, 200, and
100 mg/kg body weight; control group received a single
oral dose of 20% Tween-80 (1 ml). For the subacute tox-
icity test, mice in each group were fed with plumbagin
at a daily oral dose of 100, 50, and 25 mg/kg body
weight for 14 days; control group received a daily oral
dose 1 ml of 20% Tween-80 for 14 days [13,14]. General
behavior of each mouse was observed continuously for
1 h after each dose, intermittently every 4 h, and there-
after over a period of 24 h [15]. Animals were observed
for up to 14 days for the acute toxicity test and 28 days





P. falciparum clones (nM)
IC50 against K1
chloroquine resistant
P. falciparum clones (nM)
Plumbagin 580 (270–640) 370 (270–490)
Chloroquine 10.5 (9.4–12.1) 128.7 (109.3–139.2)
Artesunate 2.1 (1.98–2.54) 1.91 (16.1–2.1)
Data are presented as median (range) of IC50 values (nM).
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(behavioral change related to central nervous, cardiovas-
cular and gastrointestinal systems as well as complete
blood count, liver and kidney function tests), body
weight change and water and food consumption. At the
end of the observational period, all animals were sacri-
ficed under ether anesthesia and vital organs (heart,
lung, liver, spleen and kidney) were removed from all
animals for gross and histopathological examination.
Assessment of antimalarial activity of plumbagin in
Plasmodium berghei-infected mouse model
(4-day suppressive test)
The in vivo antimalarial activity of plumbagin was evalu-
ated using a 4-day suppressive test in P. berghei-infected
mouse model [16]. P. berghei (ANKA) strain used in the
experiment was obtained from the National Center for
Genetic Engineering and Biotechnology (BIOTEC),
Thailand. The parasite had been maintained by serial
blood passage in mice, and blood stage stored at −196°C
until use.
ICR mice were divided into five groups (3 males and 3
females for each group). The donor mice were infected
with 200 μl of P. berghei parasite inoculum. The parasit-
ized blood of each donor mouse was collected from the
tail vein and diluted with 0.9% sodium chloride. Mice
were infected with saline suspension of 1 × 107 parasit-
ized erythrocytes (0.2 ml) by intraperitoneal injection
(Day 0). Four hours after infection, animals were treated
with plumbagin at oral daily doses of 1, 10, or 25 mg/kg
body weight of plumbagin for four consecutive days
(test group 1, 2 and 3, respectively). Positive and
negative control groups were fed with the antimalarial
chloroquine at oral daily doses of 10 mg/kg body weight
of plumbagin and 20% Tween-80, respectively. On day
4 (96 hours post infection), parasitaemia of individual
mouse was determined under light microscope by exam-
ination of giemsa-stained thin blood smears prepared
from mouse tail blood [17]. The mean parasitaemia in
each group of mice was used to calculate the % suppres-
sion for each dose using the formula:
%Suppression ¼
Parasitaemia of negative control
−Parasitaemia of test
Parasitaemia of negative control
 100
The antimalarial activity of plumbagin was determined
from the ratio of percentage of parasite reduction in
treated and negative control groups [18]. Results are
expressed as median (range) values. Comparison of
difference in quantitative variables between more than
two and two groups was performed using Kruskal Wallis
and Mann–Whitney U tests (SPSS version 16.0, SPSS
Inc., CO, USA). Statistical significance level was set at
α < 0.05 for all tests.Results
Assessment of in vitro antimalarial activities of Plumbagin
The median IC50 values for antimalarial activity of plum-
bagin against 3D7 chloroquine-sensitive P. falciparum
and K1 chloroquine-resistant P. falciparum clones were
580 and 370 nM, respectively. The corresponding IC50
values for chloroquine and artesunate were 10.5 vs 128.7
and 2.1 vs 1.91 nM, respectively (Table 1).
Toxicity tests
The toxicity of plumbagin when given as a single oral
dose (acute toxicity) and 14-day daily doses (subacute
toxicity) in mice was investigated in order to define
optimal dose of plumbagin to be used for evaluation of
its in vivo antimalarial activity in malarial mouse model.
Results indicated virtually no toxicity of plumbagin at a
maximum single oral dose of 100 mg/kg body weight
(acute toxicity). All mice survived following a single oral
dose of 100 mg/kg body weight of plumbagin and 20%
Tween-80 (control) (Table 2). There was neither sign of
toxicity nor significant change in water and food con-
sumption and body weights of mice in both groups dur-
ing the 14 days observation period (Figure 1). Toxic
signs and symptoms including anxiety and agitation
were however observed in 6/6 and 2/6 of mice following
the doses of 500 and 200 mg/kg body weight, respect-
ively; all subsequently died within 24 hours. The gross
examination of vital organs, i.e., heart, lung, liver, spleen
and kidney in both treated (all dose levels) and control
groups were similar either in size and cell morphology.
For the subacute toxicity test, all mice survived follow-
ing daily oral doses of 25 mg/kg body weight plumbagin
and 20% Tween-80 (control) for 14 days (Table 3). There
was neither abnormality in behavior, sign of toxicity, nor
significant change in water and food consumption and
body weights during the 14 days observation period
(Figure 2). Toxic signs and symptoms including anxiety
and agitation were however observed in all mice fol-
lowing the doses of 100 and 50mg/kg body weight of
plumbagin (for 14 days). Mice receiving 100 mg/kg body
weight of plumbagin died within 4–8 days, whereas
those receiving 50 mg/kg body weight dosing died
within 8–11 days. The gross examination of vital organs,
Table 2 Number of survived ICR mice following a single (acute toxicity) and multiple (subacute toxicity) oral dosing of
plumbagin
Test group Number of mice (survived/total)
Acute toxicity Control (20% Tween-80) 6/6
Plumbagin: 500 mg/kg body weight 0/6
Plumbagin: 200 mg/kg body weight 4/6
Plumbagin: 100 mg/kg body weight 6/6
Subacute toxicity Control (Tween-80) 6/6
Plumbagin: 100 mg/kg body weight 0/6
Plumbagin: 50 mg/kg body weight 0/6
Plumbagin: 25 mg/kg body weight 6/6
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and control groups were similar in size and cell
morphology.Assessment of antimalarial activity of plumbagin in
Plasmodium berghei-infected mouse model (4-day
suppressive test)
Results of the 4-day suppressive antimalarial test of
plumbagin and chloroquine in mice infected with P. ber-
ghei ANKA strain are summarized in Table 3. Median
(range) parasite density on day 4 of the negative control
group (20% Tween-80), mice treated with 1, 10 and
25 mg/kg body weight of plumbagin, and 10 mg/kg body
weight of chloroquine for 14 days were 37.8 (46.9-41.8),
35.6 (31.7-39.6), 35.05 (31.2-38.8), 22.3 (19.2-25.7) and 0
(0–0)% respectively. Parasite density on day 4 in the
control group treated with Tween-80 was higher than
the groups treated with chloroquine and 25 mg/kg body
weight plumbagin. Chloroquine exhibited the most
potent antimalarial activity with respect to its activity on
reduction of parasitaemia on day 4 and prolongation of
survival time. Parasite density (%) on day 4 followingFigure 1 Median body weight (g) of male and female mice (n = 6 for
single oral dose of 100 mg/kg body weight of plumbagin and followichloroquine treatment (0%) was significantly lower than
20% Tween 80 (negative control) and plumbagin at all
dose levels (p < 0.05). In addition, parasite suppression
(%) of mice treated with chloroquine (100%) was signifi-
cantly higher than the negative control group (0%) and
the groups treated with 1 (5.5%), 10 (7.3%), and 25 (41%)
mg/kg/day plumbagin (p < 0.01). The survival time in
the group treated with chloroquine was also significantly
longer than the negative control and the groups treated
with plumbagin at all dose levels (p < 0.01).Discussion
Plumbagin, a naturally occurring naphthoquinone widely
distributed in the Plumbaginaceae family, has been re-
ported to possess a wide spectrum of pharmacological
properties. The crude ethanolic extract of Plumbago
indica Linn. (root) has been shown to possess good to
moderate antimalarial activity (class III antimalarial
activity) in our previous in vitro screening [8]. Among the
32 plants investigated, Plumbago indica Linn. showed the
most promising activity against both K1 chloroquine-
resistant (IC50 3 μg/ml) and 3D7 chloroquine-sensitiveeach group) during the first 14 days in the administration of a
ng Tween-80 (control) in the acute toxicity test.
Table 3 Antimalarial activity of plumbagin compared with chloroquine and negative control (treated with 20% Tween-80)
against P. berghei ANKA strain in mice (4-day suppressive test)
Treatment Dose(mg/kg body weight/day)
Parasite density





Negative control (20% Tween 80) - 37.8 (46.9-41.8)a 0 7 (6–7)
Plumbagin
1 35.6 (31.7–39.6) 5.8 7.5 (6–9)
10 35.05 (31.2–38.8) 7.3 8 (8–9)
25 22.3 (19.2–25.7) 41 10 (9–11)
Chloroquine 10 0 (0–0)b 100c > 15d
Data are presented as median (range) values (6 mice for each group) of parasite density, % suppression and survival time.
aSignificantly lower than the groups treated with 10 and 25 mg/kg body weight/day of plumbagin and 10 mg/kg body weight/day of chloroquine (p < 0.05).
bSignificantly higher than negative control and the groups treated with 1, 10 and 25 mg/kg body weight/day of plumbagin (p < 0.05).
cSignificantly higher than negative control and the groups treated with 1, 10 and 25 mg/kg body weight/day of plumbagin (p < 0.05).
dSignificantly longer than the groups treated with 1, 10 and 25 mg/kg body weight/day of plumbagin and 10 mg/kg body weight/day chloroquine (p < 0.05).
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and 21.6, respectively). Its antimalarial potency against K1
P. falciparum clone was about 2.2% of artesunate. In the
present study, promising antimalarial activity of its active
constituent plumbagin was initially demonstrated in the
in vitro assay with median IC50 values against 3D7
chloroquine-sensitive and chloroquine-resistant P. falcip-
arum clones of 580 and 370 nM, respectively. It was noted
for a relatively higher activity of plumbagin against
chloroquine-resistant P. falciparum (class I: very good
activity) compared with chloroquine-sensitive P. falcip-
arum (class II: good) clone [19]. The difference in antimal-
arial activity between the two clones could be due to the
difference in drug transportation mechanisms particularly
those involving Plasmodium falciparum chloroquine
resistance transporter (pfcrt). Parasite chromosomal loci
associated with these differential chemical phenotypes
should be investigated to clarify this issue [20]. This activ-
ity however, should be of advantage for the treatment of
patients in areas where P. falciparum is still sensitive to
chloroquine. Promising antimalarial activity was observedFigure 2 Median body weight (g) of male and female mice (n = 6 for
daily oral doses of 25 mg/kg body weight of plumbagin and Tween-8in the absence of significant toxicity both in acute and
subacute toxicity testing with dose up to 100 mg/kg body
weight and 25 mg/kg body weight/day for 14 days,
respectively.
Based on the results of the in vivo antimalarial testing,
plumbagin at the dose of 25 mg/kg body weight given
for 4 days exhibited moderate to weak antimalarial activ-
ity with regards to its inhibitory activity on the reduction
of parasitaemia and the prolongation of survival time.
The compound at daily doses of 10 mg/kg body weight/
day for 4 days showed only weak activity, while at daily
doses of 1 mg/kg body weight did not produce any
significant activity [19]. The antimalarial drug chloroquine
exhibited the most potent antimalarial activity with 100%
suppression of parasitaemia on day 4 (0% parasite density)
and a significant prolongation of survival time (> 15 days).
This result of the in vivo antimalarial activity of plumbagin
was however, inconsistent with the observed in vitro
showing the compound to be of good to moderate
antimalarial activity. Plumbagin is poorly water soluble
which results in poor absorption across gastrointestinaleach group) during the 28 days following the administration of
0 (control) in the subacute toxicity test.
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previous study, mice treated with liposomal formulation
of plumbagin was shown to achieve higher plasma and
tissue level and area under the concentration-time curve
(AUC) compared with those treated with the water-sol-
uble plumbagin. Moreover, high concentration was found
in liver and spleen of mice [22]. In vivo pharmacokinet-
ics study also demonstrated that orally administered
plumbagin produced only 39% systemic bioavailability
due to its limited biopharmaceutical properties such
as high lipophilicity (log P 3.04) and insolubility in
water [23].
Conclusions
Plumbagin at the dose of 25 mg/kg body weight given
for 4 days was safe and produced weak antimalarial activ-
ity. Chemical derivatization of the parent compound or
preparation of modified formulation is required to improve
its systemic bioavailability.
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